Pharma: If Cuts Are Included In Debt Ceiling Negotiations, Jobs Will Be Lost

Inside Health Policy’s John Wilkerson reports that the pharmaceutical industry is launching a lobbying effort against a money saving proposal that would extend Medicaid drug rebates to so-called dual eligible beneficiaries (those who qualify for both Medicare and Medicaid). Lawmakers may be considering the proposal as part of the debt ceiling negotiations. Brand name drug makers are “citing industry-funded research findings that biopharmaceutical industry revenue cuts of this magnitude would result in the loss of more than 200,000 high-paying jobs.”